Bruce Feinberg, DO; Scott Gottlieb, MD; and Ted Okon, MBA, discuss the intentions and overall impact of the 340B Drug Pricing Program on the healthcare industry.
Dr Gottlieb and Mr Okon explain that despite its good intentions, the 340B Drug Pricing Program is leading to consolidation between oncology practices and hospitals.
“A program that was meant to service hospitals that really did have diverse missions and really did service a lot of underprivileged patients has been exploited by hospitals that don’t necessarily have the same mission,” says Dr Gottlieb.
Dr Gottlieb discusses further how hospitals are exploiting the program to generate additional revenue. He also explains that this consolidation is forcing some patients to receive oncology care in a hospital setting, which is not always best. This consolidation drives up healthcare costs and can affect the overall quality of care for patients.
Mr Okon notes that specifically, disproportionate-share hospitals are affecting the success of the 340B Drug Pricing Program, and highlights figures that demonstrate the overall financial impact of this program in the oncology setting.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More